Literature DB >> 25130937

Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis.

Jacqueline G O'Leary1, K Rajender Reddy2, Florence Wong3, Patrick S Kamath4, Heather M Patton5, Scott W Biggins6, Michael B Fallon7, Guadalupe Garcia-Tsao8, Ram M Subramanian9, Raza Malik10, Leroy R Thacker11, Jasmohan S Bajaj12.   

Abstract

BACKGROUND & AIMS: Bacterial infections, particularly repeated infections, are significant causes of morbidity and mortality among patients with cirrhosis. We investigated and characterized risk factors for repeat infections in these patients.
METHODS: In a prospective study, we collected data from 188 patients hospitalized with cirrhosis and infections and enrolled in the North American Consortium for the Study of End-Stage Liver Disease (12 centers). Patients were followed up for 6 months after hospital discharge and data were analyzed on type of infections and factors associated with subsequent infections.
RESULTS: Six months after hospital discharge, 14% of subjects had received liver transplants, 27% died, and 59% were alive without liver transplantation. After discharge, 45% had subsequent infections, but only 26% of the subsequent infections occurred at the same site. Compared with patients not re-infected, patients with repeat infections were older and a higher proportion used proton pump inhibitors (PPIs) (P = .006), rifaximin (P < .001), or prophylactic therapy for spontaneous bacterial peritonitis (SBP) (P < .001). Logistic regression showed that SBP prophylaxis (odds ratio [OR], 3.44; 95% confidence interval [CI], 1.56-7.63), PPI use (OR, 2.94; 95% CI, 1.39-6.20), SBP at hospital admission (OR, 0.37; 95% CI, 0.15-0.91), and age (OR, 1.06; 95% CI, 1.02-1.11) were independent predictors of subsequent infections.
CONCLUSIONS: Patients hospitalized with cirrhosis and infections are at high risk for subsequent infections, mostly at different sites, within 6 months of index infection resolution. Those at highest risk include previously infected older patients receiving PPIs and/or SBP prophylaxis, although these associations do not prove that these factors cause the infections. New strategies are needed to prevent infections in patients with cirrhosis.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic; Complication; Decompensation; NACSELD

Mesh:

Substances:

Year:  2014        PMID: 25130937      PMCID: PMC4326601          DOI: 10.1016/j.cgh.2014.07.060

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  44 in total

1.  New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.

Authors:  Florence Wong; Jacqueline G O'Leary; K Rajender Reddy; Heather Patton; Patrick S Kamath; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Benedict Maliakkal; Leroy R Thacker; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

2.  The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.

Authors:  Mohamad A Hanouneh; Ibrahim A Hanouneh; Jana G Hashash; Ryan Law; Jamak Modaresi Esfeh; Rocio Lopez; Nyla Hazratjee; Thomas Smith; Nizar N Zein
Journal:  J Clin Gastroenterol       Date:  2012-09       Impact factor: 3.062

3.  Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections.

Authors:  Arnaud Galbois; Vincent Das; Dominique Thabut; Eric Maury; Hafid Ait-Oufella; Chantal Housset; Bertrand Guidet
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

4.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

5.  Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.

Authors:  Thomas Sersté; Christian Melot; Claire Francoz; François Durand; Pierre-Emmanuel Rautou; Dominique Valla; Richard Moreau; Didier Lebrec
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 6.  Immune dysfunction and infections in patients with cirrhosis.

Authors:  Alexander R Bonnel; Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

7.  Chronic sepsis mortality characterized by an individualized inflammatory response.

Authors:  Marcin F Osuchowski; Kathy Welch; Huan Yang; Javed Siddiqui; Daniel G Remick
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.

Authors:  Guy W Neff; Michael Jones; Mark Jonas; Ravi Ravinuthala; David Novick; Tiffany E Kaiser; Nyingi Kemmer
Journal:  J Clin Gastroenterol       Date:  2013-02       Impact factor: 3.062

Review 9.  Proton pump inhibitors in cirrhosis: tradition or evidence based practice?

Authors:  Francesca Lodato; Francesco Azzaroli; Maria Di Girolamo; Valentina Feletti; Paolo Cecinato; Andrea Lisotti; Davide Festi; Enrico Roda; Giuseppe Mazzella
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

10.  Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.

Authors:  Lucio Lombardo; Monica Foti; Olga Ruggia; Andrea Chiecchio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-06       Impact factor: 11.382

View more
  33 in total

Review 1.  Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death.

Authors:  Mary D Cannon; Paul Martin; Andres F Carrion
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

2.  Spontaneous Bacterial Peritonitis.

Authors:  Kris Kowdley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-01

3.  Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Jacqueline G OʼLeary; Puneeta Tandon; Florence Wong; Guadalupe Garcia-Tsao; Patrick S Kamath; Scott W Biggins; Jennifer C Lai; Hugo E Vargas; Benedict Maliakkal; Michael B Fallon; Paul J Thuluvath; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

4.  Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis.

Authors:  Dawei Shi; Ziye Zhou; Ying Dai; Xiaofeng Pan; Qinqin Cao
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

Review 5.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

6.  Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort.

Authors:  Jasmohan S Bajaj; Rajender K Reddy; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Michael Fallon; Benedict Maliakkal; Jennifer Lai; Hugo E Vargas; Ram M Subramanian; Paul Thuluvath; Leroy R Thacker; Jacqueline G OʼLeary
Journal:  Am J Gastroenterol       Date:  2017-12-19       Impact factor: 10.864

7.  The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.

Authors:  Jasmohan S Bajaj; K Rajender Reddy; Puneeta Tandon; Florence Wong; Patrick S Kamath; Guadalupe Garcia-Tsao; Benedict Maliakkal; Scott W Biggins; Paul J Thuluvath; Michael B Fallon; Ram M Subramanian; Hugo Vargas; Leroy R Thacker; Jacqueline G O'Leary
Journal:  Hepatology       Date:  2016-02-19       Impact factor: 17.425

Review 8.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Meng Zhang; Xin Xu; Wei Liu; Zhongwei Zhang; Qiuyu Cheng; Zhongyuan Yang; Tingting Liu; Yunhui Liu; Qin Ning; Tao Chen; Junying Qi
Journal:  Adv Ther       Date:  2021-07-25       Impact factor: 3.845

10.  Infectious Complications After Liver Transplantation.

Authors:  Maria Del Pilar Hernandez; Paul Martin; Jacques Simkins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.